var data={"title":"Sodium nitrite: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Sodium nitrite: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/8163?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=sodium-nitrite-patient-drug-information\" class=\"drug drug_patient\">see &quot;Sodium nitrite: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14600043\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hypotension and methemoglobin formation:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Sodium nitrite can cause serious adverse reactions and death in humans, even at doses less than twice the recommended therapeutic dose. Sodium nitrite causes hypotension and methemoglobin formation, which diminishes oxygen-carrying capacity. Hypotension and methemoglobin formation can occur concurrently or separately. Because of these risks, use sodium nitrite to treat acute life-threatening cyanide poisoning and use it with caution in patients in whom the diagnosis of cyanide poisoning is uncertain.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Closely monitor patients to ensure adequate perfusion and oxygenation during treatment with sodium nitrite.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Consider alternative therapeutic approaches in patients known to have diminished oxygen or cardiovascular reserve (eg, smoke inhalation victims, preexisting anemia, cardiac or respiratory compromise) and those at higher risk of developing methemoglobinemia (eg, congenital methemoglobin reductase deficiency) because they are at greater risk of potentially life-threatening adverse events related to the use of sodium nitrite.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14600029\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antidote</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14600325\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cyanide poisoning:</b> IV: <b>Note:</b> Given in conjunction with sodium thiosulfate. Administer sodium nitrite first, followed immediately by the administration of sodium thiosulfate: 300 mg (10 mL of a 3% solution); may repeat at one-half the original dose if symptoms of cyanide toxicity return. Sodium nitrite is generally discontinued for methemoglobin levels &gt;30%.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternatively,</i> in patients who are unable to tolerate significant methemoglobinemia (eg, patients with comorbidities that compromise oxygen delivery, such as heart disease, lung disease), dosing may be based on hemoglobin levels (when rapid bedside testing is available) to prevent fatal methemoglobinemia; see table (Berlin, 1970):</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Hemoglobin Level (g/dL)</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Dose of 3%</p>\n            <p style=\"text-indent:0em;\">Sodium Nitrite Solution</p>\n            <p style=\"text-indent:0em;\">(maximum dose: 10 mL)</p></th></tr></thead>\n      <tbody valign=\"top\">\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">7</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.19 mL/kg</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">8</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.22 mL/kg</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">9</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.25 mL/kg</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">10</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.27 mL/kg</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">11</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.3 mL/kg</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">12</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.33 mL/kg</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">13</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.36 mL/kg</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">14</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.39 mL/kg</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Note:</b> Monitor the patient for 24 to 48 hours; if symptoms return, repeat sodium nitrite and sodium thiosulfate at one-half the original dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14600324\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cyanide poisoning:</b> IV: 6 mg/kg (0.2 mL/kg or 6-8 mL/m<sup>2</sup> of a 3% solution); maximum dose: 300 mg (10 mL of a 3% solution); may repeat at one-half the original dose if symptoms of cyanide toxicity return. <b>Note:</b> Given in conjunction with sodium thiosulfate. Administer sodium nitrite first, followed immediately by the administration of sodium thiosulfate. Sodium nitrite is generally discontinued for methemoglobin levels &gt;30%.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternatively</i>, in patients who are unable to tolerate significant methemoglobinemia (eg, patients with comorbidities that compromise oxygen delivery, such as heart disease, lung disease): Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">\n      <b>Note:</b> Monitor the patient for 24-48 hours; if symptoms return, repeat sodium nitrite and sodium thiosulfate at one-half the original dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14600326\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. Use caution due to the likelihood of decreased renal function.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14600327\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment provided in the manufacturer&rsquo;s labeling; however, renal elimination of sodium nitrite is significant and risk of adverse effects may be increased in patients with renal impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14600328\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14600028\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14600329\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Administer via slow IV injection (2.5 to 5 mL/minute) as soon as possible after diagnosis of acute, life-threatening cyanide poisoning; follow immediately with the administration of sodium thiosulfate. Decrease the rate of infusion in the event of significant hypotension.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F247324\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cyanide poisoning:</b> Treatment of acute, life-threatening cyanide poisoning.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note: </b>The preferred antidote for the treatment of acute cyanide poisoning is hydroxocobalamin, especially in patients who have concurrent carbon monoxide poisoning (eg, smoke inhalation), significant anemia, or G6PD deficiency (Anseeuw 2013). Sodium nitrite in combination with sodium thiosulfate should be considered only if hydroxocobalamin is unavailable, there is a contraindication to the use of hydroxocobalamin, or if the patient has a known sensitivity to hydroxocobalamin or vitamin B<sub>12</sub> analogues. Consider consultation with a poison control center at 1-800-222-1222.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14600051\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Cardiac arrhythmia, flushing, hypotension, palpitations, syncope, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Anxiety, coma, confusion, dizziness, fatigue, headache, numbness, paresthesia, seizure, tingling sensation (at injection site)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Diaphoresis, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Acidosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Methemoglobinemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blurred vision</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Cyanosis, dyspnea, tachypnea</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14600047\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">There are no contraindications listed within the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F247318\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypotension: <b>[US Boxed Warning]: Sodium nitrite may cause severe hypotension resulting in diminished oxygen-carrying capacity; serious adverse effects may occur at doses less than twice the recommended therapeutic dose. Monitor for adequate perfusion and oxygenation; ensure patient is euvolemic. Use with caution in patients where the diagnosis of cyanide poisoning is uncertain, patients with pre-existing diminished oxygen or cardiovascular reserve (eg, smoke inhalation victims, anemia, substantial blood loss, and cardiac or respiratory compromise),</b> and in patients who may be susceptible to injury from vasodilation; the use of hydroxocobalamin is recommended in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Methemoglobinemia: <b>[US Boxed Warning]: Sodium nitrite may cause methemoglobin formation resulting in diminished oxygen-carrying capacity; serious adverse effects may occur at doses less than twice the recommended therapeutic dose. Monitor for adequate perfusion and oxygenation. Use with caution in patients where the diagnosis of cyanide poisoning is uncertain, patients with pre-existing diminished oxygen or cardiovascular reserve (eg, smoke inhalation victims, anemia, substantial blood loss, and cardiac or respiratory compromise), and in patients at greater risk for developing methemoglobinemia (eg, congenital methemoglobin reductase deficiency);</b> the use of hydroxocobalamin is recommended in these patients. Use with caution with concomitant medications known to cause methemoglobinemia (eg, nitroglycerin, phenazopyridine). Sodium nitrite is generally discontinued for methemoglobin levels &gt;30%. Intravenous methylene blue and exchange transfusion have been used to treat life-threatening methemoglobinemia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anemia: Use with caution; patients with anemia will form more methemoglobin. Dosage reduction in proportion to oxygen-carrying capacity is recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Glucose-6-phosphate dehydrogenase deficiency: Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency are at an increased risk for hemolytic crisis following sodium nitrite administration; consider alternative treatment options if possible. Monitor for an acute drop in hematocrit; exchange transfusion may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution; sodium nitrite undergoes substantial renal excretion. Risk for adverse events may be increased.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution due to the likelihood of decreased renal function.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fire victims: Fire victims may present with both cyanide and carbon monoxide poisoning. In this scenario, hydroxocobalamin is the agent of choice for cyanide intoxication since the induction of methemoglobinemia (due to sodium nitrite) is contraindicated until carbon monoxide levels return to normal due to the risk of severe tissue hypoxia. Methemoglobinemia decreases the oxygen-carrying capacity of hemoglobin and the presence of carbon monoxide prevents hemoglobin from releasing oxygen to the tissues. In these patients, sodium thiosulfate may be used alone to promote the clearance of cyanide; however, hydroxocobalamin is still the preferred cyanide antidote because sodium thiosulfate has a slow onset of action.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Methemoglobin reductase, which is responsible for converting methemoglobin back to hemoglobin, has reduced activity in pediatric patients. In addition, infants and young children have some proportion of fetal hemoglobin which forms methemoglobin more readily than adult hemoglobin. Therefore, pediatric patients (eg, neonates and infants &lt;6 months of age) are more susceptible to excessive nitrite-induced methemoglobinemia. Hydroxocobalamin will circumvent this problem and may be a more effective and rapid alternative.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pregnancy: Nitrites should be avoided due to fetal hemoglobin's susceptibility to oxidative stress.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Cyanide poisoning: Due to the risk for serious adverse effects, use with caution in patients where the diagnosis of cyanide poisoning is uncertain. However, if clinical suspicion of cyanide poisoning is high, treatment should not be delayed. Signs of cyanide poisoning may include altered mental status, cardiovascular collapse, chest tightness, mydriasis, nausea/vomiting, dyspnea, hyper-/hypotension, plasma lactate &ge;8 mmol/L. Treatment of cyanide poisoning should include external decontamination and supportive therapy. Consider consultation with a poison control center at 1-800-222-1222.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Initiation of treatment: Collection of pretreatment blood cyanide concentrations does not preclude administration and should not delay administration in the emergency management of highly suspected or confirmed cyanide toxicity. Pretreatment levels may be useful as postinfusion levels may be inaccurate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Return of symptoms: Patients receiving treatment for acute cyanide poisoning must be monitored for return of symptoms for 24-48 hours; repeat treatment (one-half the original dose) should be administered if symptoms return.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Smoke inhalation: Use nitrites cautiously in patients with cyanide poisoning related to smoke inhalation because methemoglobinemia and carboxyhemoglobinemia may worsen oxygen-carrying capacity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300060\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6223008\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=85782&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methemoglobinemia Associated Agents: May enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when nitric oxide is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracaine (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14600044\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14600045\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Teratogenic effects have been observed following maternal exposure to high concentrations of sodium nitrite in drinking water. Teratogenic effects were not observed in animal reproduction studies of sodium nitrite. Embryotoxic and nonteratogenic effects were observed in animal reproduction studies of sodium nitrite. Methemoglobin reductase is lower in the fetus compared to adults and may result in adverse effects due to nitrite-induced prenatal hypoxia. In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey, 2003). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20688399\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if sodium nitrite is excreted in breast milk. The manufacturer recommends that caution be exercised when administering sodium nitrite to nursing women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F247320\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor for at least 24 to 48 hours after administration; blood pressure and heart rate during and after infusion; hemoglobin/hematocrit; co-oximetry; serum lactate levels; venous-arterial PO<sub>2</sub> gradient; serum methemoglobin and oxyhemoglobin. Pretreatment cyanide levels may be useful diagnostically, but if the patient is acutely ill, do not delay sodium nitrite therapy while awaiting laboratory results.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14600060\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Sodium nitrite promotes the formation of methemoglobin which competes with cytochrome oxidase for the cyanide ion. Cyanide combines with methemoglobin to form cyanomethemoglobin, thereby freeing the cytochrome oxidase and allowing aerobic metabolism to continue.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23332179\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset: Peak effect: Methemoglobinemia: 30 to 60 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration of action: Methemoglobinemia: ~55 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: To ammonia and other metabolites</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (~40% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16570481\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Sodium Nitrite Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg/mL (10 mL): $107.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Agency for Toxic Substances and Disease Registry (ATSDR), &ldquo;Medical Management Guidelines for Hydrogen Cyanide (HCN).&rdquo; Available at <a href=\"http://www.atsdr.cdc.gov/MHMI/mmg8.pdf\" target=\"_blank\">http://www.atsdr.cdc.gov/MHMI/mmg8.pdf </a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anseeuw K, Delvau N, Burillo-Putze G, et al. Cyanide poisoning by fire smoke inhalation: a European expert consensus. <i>Eur J Emerg Med</i>. 2013;20(1):2-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-nitrite-drug-information/abstract-text/22828651/pubmed\" target=\"_blank\" id=\"22828651\">22828651</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bailey B, &quot;Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?&quot; <i>Birth Defects Res A Clin Mol Teratol</i>, 2003, 67(2):133-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-nitrite-drug-information/abstract-text/12769509/pubmed\" target=\"_blank\" id=\"12769509\">12769509</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bebarta VS, Pitotti RL, Borys DJ, et al, &ldquo;Seven Years of Cyanide Ingestions in the USA: Critically Ill Patients are Common, but Antidote Use is Not,&rdquo; <i>Emerg Med J</i>, 2011, 28(2):155-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-nitrite-drug-information/abstract-text/20511644/pubmed\" target=\"_blank\" id=\"20511644\">20511644</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berlin CM, &ldquo;The Treatment of Cyanide Poisoning in Children,&rdquo; <i>Pediatrics</i>, 1970, 46(5):793-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-nitrite-drug-information/abstract-text/4320419/pubmed\" target=\"_blank\" id=\"4320419\">4320419</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Geller RJ, Barthold C, Saiers JA, et al, &quot;Pediatric Cyanide Poisoning: Causes, Manifestations, Management, and Unmet Needs,&quot; <i>Pediatrics</i>, 2006, 118(5):2146-58.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-nitrite-drug-information/abstract-text/17079589/pubmed\" target=\"_blank\" id=\"17079589\">17079589</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gracia R and Shepherd G, &quot;Cyanide Poisoning and Its Treatment,&quot; <i>Pharmacotherapy</i>, 2004, 24(10):1358-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-nitrite-drug-information/abstract-text/15628833/pubmed\" target=\"_blank\" id=\"15628833\">15628833</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hall AH, Dart R, and Bogdan G, &ldquo;Sodium Thiosulfate or Hydroxocobalamin For The Empiric Treatment of Cyanide Poisoning?&rdquo; <i>Ann Emerg Med</i>, 2007, 49(6):806-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-nitrite-drug-information/abstract-text/17098327/pubmed\" target=\"_blank\" id=\"17098327\">17098327</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Howland MA, &ldquo;Antidotes in Depth: Sodium and Amyl Nitrite,&rdquo; <i>Goldfrank's Toxicologic Emergencies</i>, 10th ed, Hoffman RS, Howland MA, Lewin NA, et al, eds, New York, NY: McGraw-Hill Companies, Inc, 2015, 1612-1614.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reade MC, Davies SR, Morley PT, et al, &ldquo;Review Article: Management of Cyanide Poisoning,&rdquo; <i>Emerg Med Australas</i>, 2012, 24(3):225-38.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-nitrite-drug-information/abstract-text/22672162/pubmed\" target=\"_blank\" id=\"22672162\">22672162</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sodium nitrite injection [prescribing information]. Scottsdale, AZ: Hope Pharmaceuticals; February 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens J, El-Shammaa E, LoVecchio F. Carbon monoxide and cyanide poisoning in smoke inhalation victims: a review. <i>Trauma Reports</i>. 2015;16(1):1-11.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thompson JP and Marrs TC, &ldquo;Hydroxocobalamin in Cyanide Poisoning,&rdquo; <i>Clin Toxicol</i>, 2012, 50(10):875-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-nitrite-drug-information/abstract-text/23163594/pubmed\" target=\"_blank\" id=\"23163594\">23163594</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 85782 Version 69.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F14600043\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F14600029\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F14600325\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F14600324\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F14600326\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F14600327\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F14600328\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F14600028\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F14600329\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F247324\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F14600051\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F14600047\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F247318\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300060\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6223008\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F14600044\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F14600045\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20688399\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F247320\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F14600060\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F23332179\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16570481\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/85782|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=sodium-nitrite-patient-drug-information\" class=\"drug drug_patient\">Sodium nitrite: Patient drug information</a></li></ul></div></div>","javascript":null}